N-[(3-Cycloheptyl-1,2,4-oxadiazol-5-yl)methyl]cyclopropanamine

Catalog No.: 
ACSRZI413
CAS No.: 
1423117-12-7
Molecular Formula: 
C13H21N3O
Molecular Weight: 
235.33
N-[(3-Cycloheptyl-1,2,4-oxadiazol-5-yl)methyl]cyclopropanamine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$640.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-[(3-Cycloheptyl-1,2,4-oxadiazol-5-yl)methyl]cyclopropanamine
IUPAC NameN-((3-cycloheptyl-1,2,4-oxadiazol-5-yl)methyl)cyclopropanamine
MDL No.MFCD21520104
Molecular FormulaC13H21N3O
Molecular Weight235.33
SMILESC1(NCC2=NC(C3CCCCCC3)=NO2)CC1
InChI KeyPLBKXOSUYNGUNA-UHFFFAOYSA-N
Synonym1,2,4-Oxadiazole-5-methanamine, 3-cycloheptyl-N-cyclopropyl-;n-((3-Cycloheptyl-1,2,4-oxadiazol-5-yl)methyl)cyclopropanamine
CAS No.1423117-12-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACSRZI413 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNQUT007 route compound structure diagram
    ACNQUT00718600-39-0In Stock
  4. Then
  5. ACSRZI413 route product structure diagram
    ACSRZI4131423117-12-7
Inquiry

2. ACSRZI413 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACNQUT007 route compound structure diagram
    ACNQUT00718600-39-0In Stock
  4. Then
  5. ACSRZI413 route product structure diagram
    ACSRZI4131423117-12-7
Inquiry

3. ACSRZI413 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACSRZI413 route product structure diagram
    ACSRZI4131423117-12-7
Inquiry

Comments (0)